This MA chair secured a place in history by putting the needs of a public health program ahead of his company's commercial interest. In doing so, he won serious policy credibility for the association, leading to an era of high standing with government and influence. His company and the industry have won in the long term.
The key is leading with good ideas that will make the system better
March 11, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Medicines Australia seeks answers on AI in HTA process
September 23, 2026 - - Latest News -
The prevention gap and inside Sally Panton's bet on cellular health
September 23, 2026 - - Latest News -
Pfizer 'deeply disappointed' in response to PBAC refusing to move on price
September 23, 2026 - - Latest News -
Lilly goes direct with a patient platform for its non-PBS medicines
September 23, 2026 - - Latest News -
A 'multistakeholder' reference group to shadow agreement negotiations
September 23, 2026 - -
If there is a productivity gain in the process, then it should be passed on
September 22, 2026 - - Latest News -
Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - - Latest News
